Relay Therapeutics, Inc. Common Stock (RLAY) — Analysis Summary
Relay Therapeutics, Inc. Common Stock (RLAY) has a market cap of $2.43B with year-over-year revenue growth of -60.8%. Net margin stands at -3374.7%. The stock trades at a P/E ratio of -7.2.
Key Takeaways
- Revenue changed -60.8% year-over-year
- Net margin of -3374.7%
- P/E ratio of -7.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, RLAY posted revenue growth of -60.8% and trades at a P/E of -7.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.